Orient Europharma Co

Orient Europharma Co EBITDA per Share

The EBITDA per Share of Orient Europharma Co (4120.TWO) as of Nov 3, 2026 is -3.44 TWD. In the previous year, EBITDA per Share was 0.17 TWD — a change of -2,073.85% (lower).

EBITDA per Share

-3.44TWD

YoY

-2,073.85%

Last updated:

EBITDA per Share of Orient Europharma Co is 2025 -3.44 TWD. EBITDA per Share of Orient Europharma Co was 2024 0.17 TWD. It decreases by -2,073.85% lower compared to the previous year.

The Orient Europharma Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
4.12 TWD
Jan 1, 2019
3.88 TWD
Jan 1, 2020
1.35 TWD
Jan 1, 2021
1.28 TWD
Jan 1, 2022
-3.18 TWD
Jan 1, 2023
0.87 TWD
Jan 1, 2024
0.17 TWD
Jan 1, 2025
-3.44 TWD
The Orient Europharma Co EBITDA per Share history
YEAREBITDA per ShareYoY
-3.44TWD-2,073.85%
0.17TWD-79.82%
0.87TWD-127.21%
-3.18TWD-348.55%
1.28TWD-5.46%
1.35TWD-65.12%
3.88TWD-5.82%
4.12TWD-17.97%
5.02TWD-3.09%
5.18TWD+71.07%
3.03TWD+23.47%
2.45TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Europharma Co Stock analysis

What does Orient Europharma Co do? Orient Europharma Co Ltd manufactures and trades western medicine, health food, and cosmetics. The company operates in the nutritious healthcare products and medical cosmetic products segment, offering infant milk powders, nutritious products, and functional healthcare products. It also provides dermatological preparations, medical hair care series, organic skin care series, and medical make-up products. In the western drugs segment, the company supplies products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases, and asthma. The company's primary customers include consumers seeking healthcare solutions and beauty products. Its products are sold under the company's own brand, targeting health-conscious individuals and those requiring medical-grade skincare and pharmaceuticals. The firm's segments focus on delivering specialized products for specific health conditions and cosmetic needs. Orient Europharma Co Ltd generates revenue through the sale of its manufactured and traded products across multiple segments. The nutritious healthcare products segment contributes to sales of infant milk powders and functional healthcare items, while the medical cosmetic products segment drives sales of dermatological and organic skincare lines. The western drugs segment supports revenue through pharmaceuticals for chronic and acute medical conditions. Orient Europharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Europharma Co stock

EBITDA per Share of Orient Europharma Co is -3.44 TWD in 2025.

EBITDA per Share of Orient Europharma Co changed from 0.17 TWD to -3.44 TWD, representing a -2,073.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Orient Europharma Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Orient Europharma Co

All Key Metrics — Orient Europharma Co